Physician profile
Cheryl Bunk
NPI 1285730663
$4,381.81
in general payments reported to CMS, 2019-2025
26 companies · $778 in 2025
The $778 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $424 · 2022: $923 · 2023: $1,121 · 2024: $1,136 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,035.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $904.41 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $665.47 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $542.29 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $358.96 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $345.98 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $285.79 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $230.04 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $159.53 | 2022-2023 | |
| Exact Sciences Corporation | $152.24 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $141.00 | 2022-2024 | |
| Abbvie INC. | $74.26 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $66.86 | 2022-2025 | |
| Verona Pharma, INC. | $61.30 | 2025 | Ohtuvayre |
| Biohaven Pharmaceutical Holding Company Ltd. | $54.66 | 2022 | |
| Phathom Pharmaceuticals, INC. | $53.05 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $44.49 | 2021 | |
| Kyowa Kirin, INC. | $44.06 | 2023 | Crysvita |
| Dexcom, INC. | $37.85 | 2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $29.25 | 2021 | |
| Amarin Pharma, INC. | $25.49 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.64 | 2023 | Nuzyra |
| Novartis Pharmaceuticals Corporation | $19.32 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.00 | 2025 | Caplyta |
| Abbott Laboratories | $16.69 | 2025 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $15.57 | 2025 | Austedo Xr |
| Nestle Healthcare Nutrition INC. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Bunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.